Stuart L. Silverman

Stuart L. Silverman's AcademicInfluence.com Rankings

Stuart L. Silverman

Philosophy

#9516

World Rank

#13089

Historical Rank

Logic

#6490

World Rank

#8011

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Stuart L. Silverman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Stuart L. Silverman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Risk of new vertebral fracture in the year following a fracture. (2001) (1721)
Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research (2007) (1562)
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. (2000) (1055)
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards (2011) (915)
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. (2006) (694)
The clinical consequences of vertebral compression fracture. (1992) (607)
Fractures Attributable to Osteoporosis: Report from the National Osteoporosis Foundation (1997) (546)
International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. (2008) (538)
Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. (1996) (457)
Obesity is not protective against fracture in postmenopausal women: GLOW. (2011) (451)
A systematic review of persistence and compliance with bisphosphonates for osteoporosis (2007) (443)
The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group (2014) (414)
Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. (2008) (398)
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3‐Year, Randomized, Placebo‐, and Active‐Controlled Clinical Trial (2008) (397)
Incidence of atypical nontraumatic diaphyseal fractures of the femur (2012) (378)
The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. (2001) (345)
Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention (2012) (342)
Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. (2008) (326)
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study (2005) (323)
Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society (2010) (323)
From randomized controlled trials to observational studies. (2009) (320)
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis (2012) (295)
Deterioration in Quality of Life Following Hip Fracture: A Prospective Study (2000) (280)
Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. (2009) (268)
Decreased incidence of hip fracture in Hispanics, Asians, and blacks: California Hospital Discharge Data. (1988) (252)
Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. (1996) (213)
Relationship of Weight, Height, and Body Mass Index With Fracture Risk at Different Sites in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women (GLOW) (2014) (211)
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study (2006) (183)
Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. (2009) (181)
Salmon calcitonin: a review of current and future therapeutic indications (2008) (178)
Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. (1996) (155)
Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study (2011) (153)
Therapeutic options (1991) (129)
Standardising the descriptive epidemiology of osteoporosis: recommendations from the Epidemiology and Quality of Life Working Group of IOF (2013) (127)
National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges (2012) (126)
The Utility and Limitations of FRAX: A US Perspective (2010) (118)
The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures (2012) (115)
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data (2009) (115)
The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)—quality of life during the first 4 months after fracture (2013) (114)
Increasing hip fracture incidence in California Hispanics, 1983 to 2000 (2004) (107)
Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry (2008) (107)
When, Where and How Osteoporosis-Associated Fractures Occur: An Analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW) (2013) (106)
Balloon kyphoplasty and vertebroplasty in the management of vertebral compression fractures (2011) (102)
Osteonecrosis of the Jaw: More Research Needed (2006) (94)
Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women (2012) (92)
International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates (2017) (91)
The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis. (2009) (89)
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design (2009) (88)
Individualizing osteoporosis therapy (2012) (87)
Quality of life in osteoporosis: reliability, consistency, and validity of the Osteoporosis Assessment Questionnaire. (1998) (86)
Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. (2006) (83)
Oral bisphosphonate compliance and persistence: a matter of choice? (2010) (81)
Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW) (2010) (81)
Official Positions for FRAX® clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. (2011) (80)
The Analgesic Role of Calcitonin Following Osteoporotic Fracture (2002) (78)
Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures—results from the ICUROS (2018) (77)
Osteonecrosis of the jaws and bisphosphonates (2008) (76)
A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture (2015) (75)
Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. (2009) (74)
Effect of Bone Density Information on Decisions About Hormone Replacement Therapy: A Randomized Trial (1997) (73)
The Comparative Burden of Chronic Widespread Pain and Fibromyalgia in the United States (2016) (72)
Burden of Fibromyalgia and Comparisons With Osteoarthritis in the Workforce (2009) (68)
Quality-of-life issues in osteoporosis (2005) (66)
Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. (2005) (63)
Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study (2013) (61)
The role of socioeconomic status on hip fracture (2006) (59)
Primary non-adherence to bisphosphonates in an integrated healthcare setting (2013) (59)
Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study (2014) (58)
Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. (2004) (57)
Fibromyalgia and Chronic Pain Syndromes (2016) (56)
Report of the International Society for Clinical Densitometry 2007 Adult Position Development Conference and Official Positions (2008) (56)
Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. (2018) (52)
Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW) (2014) (52)
The Osteoporosis Assessment Questionnaire (OPAQ): A reliable and valid disease-targeted measure of health-related quality of life (HRQOL) in osteoporosis (2000) (50)
The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women. (2003) (48)
Bone loss or lost bone: Rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss (2009) (48)
Comparison of Fracture, Cardiovascular Event, and Breast Cancer Rates at 3 Years in Postmenopausal Women with Osteoporosis (2004) (47)
The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results (2013) (47)
Recommendations for the Clinical Evaluation of Agents for Treatment of Osteoporosis: Consensus of an Expert Panel Representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF) (2007) (47)
Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. (2007) (47)
Obesity, Health-Care Utilization, and Health-Related Quality of Life After Fracture in Postmenopausal Women: Global Longitudinal Study of Osteoporosis in Women (GLOW) (2014) (45)
Identifying Fibromyalgia‐Associated Symptoms and Conditions from a Clinical Perspective: A Step Toward Evaluating Healthcare Resource Utilization in Fibromyalgia (2010) (45)
Thrombocytopenia and intravenous heroin use. (1978) (44)
New Selective Estrogen Receptor Modulators (SERMs) in Development (2010) (42)
Psychometric Properties of the Osteoporosis-Specific Morisky Medication Adherence Scale in Postmenopausal Women with Osteoporosis Newly Treated with Bisphosphonates (2012) (42)
Review of adherence to medications for the treatment of osteoporosis (2006) (42)
What’s in a name? What constitutes the clinical diagnosis of osteoporosis? (2012) (41)
Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW) (2012) (41)
Quality of life measurement in osteoporosis. (1997) (41)
Rationale for the potential use of calcitonin in osteoarthritis. (2005) (39)
Compliance and persistence with osteoporosis therapies (2008) (39)
Recent developments in bisphosphonate therapy. (2007) (39)
The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis* (2009) (39)
Toward characterization and definition of fibromyalgia severity (2010) (38)
An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study* (2006) (38)
Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid (2010) (38)
Fracture risk following intermission of osteoporosis therapy (2019) (37)
Characteristics associated with anti-osteoporosis medication use: data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort. (2012) (36)
Compliance and persistence with osteoporosis medications: A critical review of the literature (2010) (36)
An appendix to the 2012 IOF–ECTS guidelines for the management of glucocorticoid-induced osteoporosis (2012) (36)
Commentary: The Five Ws of a Fracture Liaison Service: Why, Who, What, Where, and How? In Osteoporosis, We Reap What We Sow (2013) (36)
Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial (2012) (34)
Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women (2012) (33)
Sclerostin (2010) (33)
Antibodies to Epstein—Barr Viral Antigens in Early Rheumatoid Arthritis (1981) (32)
International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study (2014) (32)
Reduced Fracture Rates Observed Only in Patients With Proper Persistence and Compliance With Bisphosphonate Therapies (2007) (32)
Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis (2013) (32)
Risk of Severe Gastrointestinal Events in Women Treated with Monthly Ibandronate or Weekly Alendronate and Risedronate (2009) (31)
Health-related quality of life in osteoporosis clinical trials. The Osteoporosis Quality of Life Study Group. (1993) (30)
Primary Care Physicians’ Perceptions of the Challenges and Barriers in the Timely Diagnosis, Treatment and Management of Fibromyalgia (2011) (28)
Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies (2013) (28)
Glucocorticoid-induced osteoporosis: a cross-sectional study (1991) (28)
Tolerability of risedronate in postmenopausal women intolerant of alendronate (2001) (27)
Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS (2018) (27)
An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX® (2013) (27)
A musculoskeletal syndrome in intravenous heroin users: association with brown heroin. (1977) (26)
Glucocorticoid-induced osteoporosis (2009) (25)
Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group (2016) (25)
Validation of the Osteoporosis-Specific Morisky Medication Adherence Scale in long-term users of bisphosphonates (2014) (24)
Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective. (2014) (24)
Calcitonin : Management of osteoporosis, 1997 (1997) (24)
Osteoporosis Self-management:Choices For Better Bone Health (2004) (24)
Evaluation of a Multimodal, Direct‐to‐Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial (2018) (24)
Anabolic Therapies (2010) (23)
Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products (2016) (22)
Redefining osteoporosis treatment: Who to treat and how long to treat. (2006) (22)
Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective (2015) (22)
Impact of fractures on quality of life in patients with osteoporosis: a US cross-sectional survey (2019) (22)
Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis (2007) (21)
Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood. (2020) (20)
Real‐World Evaluation of Health‐Care Resource Utilization and Costs in Employees with Fibromyalgia Treated with Pregabalin or Duloxetine (2011) (20)
The importance of aspects of treatment for fibromyalgia (fibrositis). Differences between patient and physician views. (1990) (20)
Health-related quality of life and treatment of postmenopausal osteoporosis: results from the HORIZON-PFT. (2011) (19)
Bisphosphonate use in conditions other than osteoporosis (2011) (19)
Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate. (2009) (19)
Twice Daily Versus Once Nightly Dosing of Pregabalin for Fibromyalgia: A Double‐Blind Randomized Clinical Trial of Efficacy and Safety (2014) (18)
Sensitivity and specificity of radiographic characteristics in atypical femoral fractures (2016) (18)
Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy (2013) (18)
Improved GI Tolerability with Monthly Ibandronate in Women Previously Using Weekly Bisphosphonates (2009) (18)
Osteoporosis Therapies: Evidence from Health-Care Databases and Observational Population Studies (2010) (18)
Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) Study (2005) (18)
Healthy users, healthy adherers, and healthy behaviors? (2011) (17)
The impact of 'best-practice' patient care in fibromyalgia on practice economics. (2012) (17)
Rachitic syndrome after disodium etidronate therapy in an adolescent. (1994) (16)
Occasional Review: Use of hyperbaric oxygen in rheumatic diseases: case report and critical analysis (1995) (16)
Evaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetine (2010) (16)
Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study (2018) (16)
Selecting patients for osteoporosis therapy (2006) (15)
Measuring health-related quality of life (HRQOL) in osteoporotic males using the Male OPAQ (2012) (15)
Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression (2009) (14)
Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies (2018) (14)
Electronic medical record data to identify variables associated with a fibromyalgia diagnosis: importance of health care resource utilization (2015) (13)
Bisphosphonate-related atypical femoral fracture: Managing a rare but serious complication (2018) (13)
Progression of fibromyalgia: results from a 2-year observational fibromyalgia and chronic pain study in the US (2016) (13)
Use of FRAX®-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy. (2014) (13)
The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy. (2010) (12)
New therapies for osteoporosis: Zoledronic acid, bazedoxifene, and denosumab (2009) (12)
Management of corticosteroid-induced osteoporosis: A clinician's perspective (1992) (12)
Adherence to medications for the treatment of osteoporosis. (2006) (12)
A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention material (2016) (12)
Selecting Patients for Osteoporosis Therapy (2009) (11)
Harmonization of commercial assays for PINP; the way forward (2020) (11)
Sustained efficacy of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled study (2010) (11)
Osteoporosis Assessment Questionnaire-Physical Function (OPAQ-PF): a psychometrically validated osteoporosis-targeted patient reported outcome measure of daily activities of physical function (2014) (10)
Clinical risk factors for fracture among postmenopausal patients at risk for fracture: a historical cohort study using electronic medical record data (2011) (10)
Identification of a potential fibromyalgia diagnosis using random forest modeling applied to electronic medical records (2015) (9)
Self-perception of fracture risk: what can it tell us? (2017) (9)
Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine. (2013) (9)
Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan (2021) (8)
The Duration and Safety of Osteoporosis Treatment: Anabolic and Antiresorptive Therapy (2016) (7)
Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women (2021) (7)
Identification of a potential fibromyalgia diagnosis using random forest modeling applied to electronic medical records. (2015) (7)
Medication Decision-making in Osteoporosis: Can We Explain Why Patients Do Not Take Their Osteoporosis Medications? (2018) (7)
Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis? (2007) (6)
Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment (2020) (6)
Effect of Baseline Characteristics on the Pain Response to Pregabalin in Fibromyalgia Patients with Comorbid Depression (2018) (6)
Fibromyalgia Outcomes Over Time: Results from a Prospective Observational Study in the United States (2016) (6)
Development of the osteoporosis assessment questionnaire—physical function (OPAQ-PF): an osteoporosis-targeted, patient-reported outcomes (PRO) measure of physical function (2013) (6)
Measuring Osteoporosis Quality: The Work of the Joint Commission (2013) (5)
Use of health-related quality of life measures to predict health utility in postmenopausal osteoporotic women: results from the Multiple Outcomes of Raloxifene Evaluation study (2013) (5)
Potential drug-drug and drug-condition interactions among fibromyalgia patients initiating pregabalin or duloxetine: prevalence and health care expenditure impact. (2014) (5)
New bone density report format influences patient compliance in filling prescriptions for osteoporosis (2002) (5)
Health-related quality of life in osteoporosis clinical trials urinary calcium loss (2005) (5)
Bisphosphonate drug holidays: we reap what we sow (2016) (5)
Selecting Patients for Osteoporosis Therapy (2007) (4)
Psychometric properties of the osteoporosis assessment questionnaire (OPAQ) 2.0: results from the multiple outcomes of raloxifene evaluation (MORE) study (2014) (4)
Comparison of FRAX Scores of Southern California Females of Mexican Descent Using US Hispanic and Mexico Database (2011) (4)
A NEW AND MORE ACCURATE TECHNIC FOR INJECTING THE SUPERIOR MAXILLARY DIVISION (1923) (4)
Failure to perceive increased risk of fracture in women aged 55 years and older. The global longitudinal study of osteoporosis in women (2009) (4)
Efficient practices associated with diagnosis, treatment and management of fibromyalgia among primary care physicians. (2011) (4)
Effect of teriparatide compared with risedronate on back pain and incident vertebral fractures in postmenopausal women with osteoporotic vertebral fractures (2011) (4)
FRACTURE PATTERNS WITH SELECTIVE SEROTONIN RECEPTOR INHIBITOR, PROTON PUMP INHIBITOR AND GLUCOCORTICOIDS USE IN GLOW (2014) (3)
Bisphosphonates and atypical femoral fractures. (2010) (3)
Identifying Individuals at Risk for Fracture in Guatemala (2011) (3)
Risedronate treatment of postmenopausal women with low bone mass: Preliminary data (2006) (3)
Compliance and persistence with osteoporosis therapies: we can do better (2007) (3)
Comorbidity indices for clinical trials: adaptation of two existing indices for use with the FREEDOM trial in women with postmenopausal osteoporosis (2015) (3)
Individualizing osteoporosis medications (2014) (3)
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 Year results from the MOBILE study (Annals of the Rheumatic Diseases (2006) 65, (654-661)) (2008) (3)
Lessons from osteoporosis clinical trials (2006) (3)
Is Denosumab Cost-Effective Compared To Oral Bisphosphonates For The Treatment Of Male Osteoporosis (Mop) In Sweden? (2013) (2)
Evaluation of Risk for Osteoporotic Fracture (2008) (2)
Fracture efficacy of monthly ibandronate and weekly bisphosphonate therapy: a retrospective cohort study (2008) (2)
Principles and practice of oral surgery (2)
DENOSUMAB DECREASES CORTICAL POROSITY IN POSTMENOPAUSAL WOMEN WITH LOW BONE MINERAL DENSITY (2011) (2)
Bisphosphonate Therapy and Hip Fractures Within the Risedronate and Alendronate (REAL) Cohort Study: Subgroup With Prior Fracture (2008) (2)
Defining Zoledronate’s Duration of Action and Optimal Dosing Interval for an Effective Therapy (2010) (2)
Erratum to: Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy (2013) (2)
Nasal calcitonin (2007) (2)
Oral Surgical Anatomy (1927) (1)
Commentary: Measuring Quality of Care in Osteoporosis (2013) (1)
Tolerability of monthly oral ibandronate in postmenopausal osteoporosis: 1-year results from the MOBILE Study (2004) (1)
Efficacy and adverse event profile of monthly oral ibandronate during the first year of the mobile long-term extension study (2007) (1)
PND5 COMPARISON OF DIRECT AND INDIRECT COSTS IN EMPLOYEES WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY TREATED WITH PREGABALIN OR DULOXETINE (2010) (1)
World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2015): Poster Abstracts (2015) (1)
The PREFER-US Study: An Evaluation of Patient Preferences for Osteoporosis Medications and Their Attributes (2006) (1)
Multinational comparison of bone health in women 55 years of age and older The global longitudinal study of osteoporosis in women (2009) (1)
Reports of Depression in Older Women with Osteoporosis (2014) (1)
Increases in Bone Mineral Density with Once-Monthly Ibandronate: A Post Hoc Responder Rate Analysis of the MOBILE Study (2006) (1)
(131) Transitions among chronic pain and fibromyalgia patients: results from a two-year observational fibromyalgia study in the United States (2015) (1)
Drug utilization, clinical and economic outcomes of patients with osteoarthritis of the hip and/or knee treated with long-term use of traditional NSAIDs, topical NSAIDs, and COX-2 inhibitors (2022) (1)
Chapter 17 – Calcitonin in the Treatment of Osteoporosis (2006) (1)
The Status of Apicoectomy (1918) (1)
Quality of Life in Patients with Osteoporosis: A Us Cross-Sectional Survey (2018) (1)
Zoledronic acid reduces recurrent clinical fracture in patients with hip fracture (2009) (1)
Oral communications abstracts (2007) (0)
Reply to the Letter by E. Czerwinski Regarding “The Utility and Limitations of FRAX: A US Perspective” (2012) (0)
211) Economic burden of chronic widespread pain and fibromyalgia in the US (2014) (0)
Impact of efficient practices in the care of patients with fibromyalgia (2011) (0)
THU0490 Temporal increases in side effect concerns of osteoporosis medications among women with previous fractures (2018) (0)
Monthly ibandronate use is associated with a high percentage of BMD responders (2007) (0)
Compliance Continuum and Fracture Risk Reduction with Bisphosphonate Treatment for Osteoporosis (2006) (0)
Review Article Sclerostin (2010) (0)
HOW WELL DOES SELF-PERCEPTION OF FRACTURE RISK RELATE TO FRACTURE PROBABILITY USING FRAX? FINDINGS FROM THE GLOW STUDY (2014) (0)
Monthly Ibandronate Reduces Serum CTX Within Three Days of Treatment Initiation and Maintains a Monthly Pattern of Serum CTX Suppression (2008) (0)
Suppression of Bone-Turnover Markers at 3 months is Maintained at 2 Years with Once-Monthly Ibandronate: MOBILE 2-Year Data (2006) (0)
THU0472 Factors associated with readiness for adopting osteoporosis treatment change (2018) (0)
Fragility Fractures and Health Status in a Multinational Cohort. The Global Longitudinal Registry of Osteoporosis in Women. (2008) (0)
Risedronate is well tolerated in osteoporotic patients, including those older than 80 years (2002) (0)
Pharmacology, Action and Toxicity of Various local Anesthetics (1920) (0)
Osteoporosis, An Issue of Rheumatic Disease Clinics (2011) (0)
A Musculoskeletal Syndrome in Intravenous Heroin Users (2020) (0)
A Study of the Disputed Points in Local Anesthesia (1917) (0)
POS0283 TREATMENT PATTERNS AND CLINICAL CHARACTERISTICS OF PATIENTS WITH OSTEOARTHRITIS OF THE HIP AND/OR KNEE TREATED WITH TRADITIONAL NSAIDS VS COX-2S: A REAL-WORLD STUDY OF COMMERCIALLY-INSURED PATIENTS (2021) (0)
Comprar Osteoporosis, An Issue of Rheumatic Disease Clinics | Stuart L. Silverman | 9781455779918 | Saunders (2012) (0)
Once-monthly oral ibandronate (boniva) has favorable safety and tolerability in postmenopausal women with osteoporosis: 2-year results from MOBILE. (2005) (0)
Association Between Adherence to Bisphosphonate Therapy and Reduced Nonvertebral Fracture Risk (2006) (0)
Modelling of Serum CTX Levels with Daily and Monthly Oral Ibandronate (2006) (0)
ANTIOSTEOPOROSIS MEDICATION USE REMAINS LOW AFTER FRACTURE BUT IS RELATED TO SELF PERCEIVED FRACTURE RISK: FINDINGS FROM THE GLOW STUDY (2014) (0)
A Study of the Disputed Point in Local Anesthesia (1917) (0)
Women are more persistent with monthly ibandronate versus weekly bisphosphonates (2007) (0)
Atypical Neuralgias and Their Treatment (1924) (0)
FRACTURE INCIDENCE IN OBESE POSTMENOPAUSAL WOMEN: THE GLOBAL STUDY OF OSTEOPOROSIS IN WOMEN (GLOW) (2012) (0)
PMS20 Frequency of Initiating Pain Treatment with and Timing to Switching to Opioids Among Privately-Insured Patients with Osteoarthritis (2021) (0)
DISTRIBUTION OF RISK FACTORS FOR FRACTURE IN WOMEN WITH AND WITHOUT A FRACTURE HISTORY: A REGIONAL COMPARISON. THE GLOBAL LONGITUDINAL STUDY OF OSTEOPOROSIS IN WOMEN (2008) (0)
Once-monthly ibandronate improves GI tolerability in postmenopausal women transitioned from a weekly bisphosphonate (2007) (0)
PMS40 Cost-Effectiveness of Denosumab for the Treatment of Male Osteoporosis (MOP) in the Elderly in Sweden (2012) (0)
Further Studies in Trigeminal Neuralgia (1923) (0)
Adverse Health Outcomes in Men with Osteoporosis (2010) (0)
PMS3 Risk Factors Associated with Falls and Fractures Followed by Opioid Prescription among Privately-Insured Patients with Osteoarthritis (2021) (0)
Failure to Perceive Increased Risk of Fracture in Women >= 55 Years. The Global Longitudinal Registry of Osteoporosis in Women (2008) (0)
Fracture Rates With Monthly Oral Ibandronate and Weekly Bisphosphonates: The Evaluation of Ibandronate Efficacy (VIBE) Database Fracture Study (2008) (0)
Understanding Physicians’ Perceptions of Patient-Identified Barriers to Osteoporosis Medication Initiation: A Cognitive Mapping Approach (2022) (0)
9 – Calcitonin Treatment in Postmenopausal Osteoporosis (2000) (0)
Osteoporosis and the new absolute fracture risk algorithm (2008) (0)
Selecting patients for osteoporosis therapy: the new WHO paradigm (2006) (0)
Methodology questioned. (2008) (0)
Salmon Calcitonin in the Treatment of Osteoporosis (2006) (0)
Title New Selective Estrogen Receptor Modulators ( SERMs ) in Development Permalink (2010) (0)
Adherence to Osteoporosis Therapies (2018) (0)
PMS67 EXPERIENCE AND PREFERENCE-BASED EQ-5D-3L VALUE SET DERIVED FROM LONGITUDINAL DATA: RESULTS FROM THE INTERNATIONAL COSTS AND UTILITIES OF OSTEOPOROTIC FRACTURES STUDY (ICUROS) (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Stuart L. Silverman?

Stuart L. Silverman is affiliated with the following schools:

University of California, Los Angeles

Stuart L. Silverman's Academic­Influence.com Rankings

Why Is Stuart L. Silverman Influential?

Stuart L. Silverman's Published Works

Published Works

What Schools Are Affiliated With Stuart L. Silverman?

Stuart L. Silverman's AcademicInfluence.com Rankings